Once more, the miracle drug Gleevec, takes center stage.
The leukemia drug Gleevec, though hugely successful has some downsides too: heart failure in a few patients as shown in previous studies and now, drug resistance continues to be a problem.
Now, Kimmel Cancer Center at Thomas Jefferson University may have discovered a way to sidestep such resistance by reactivating a protein that is normally shut off in leukemia and in Gleevec-resistant cancer cells, leukemia development is halted.
A drug that could turn on the gene that makes the protein C/EBP-alpha, a “transcription factor” required for cells to differentiate, then, might control or …read more